3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency
An Open-Label Study of Two Different Doses of 3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution When Used as an Aid for Ureteral Patency
Sponsor: Prove pharm
Listed as NCT04228445, this PHASE3 trial focuses on Ureter Injury and remains completed. Sponsored by Prove pharm, it has been updated 7 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2021 — Dec 2022 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
May 2021 — Sep 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Jan 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE3
-
Feb 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Prove pharm
For direct contact, visit the study record on ClinicalTrials.gov .